Court Rules Taiwanese Company Infringed on Supernus’ Oxtellar Patents

A New Jersey federal court ruled that a Taiwanese firm infringed on patents held by Maryland-based drugmaker Supernus.

The court ruled that TWi Pharmaceuticals infringed on three of Supernus’ patents in its ANDA for a generic version of Oxtellar (oxcarbazepine), used to treat central nervous system diseases such as epilepsy.

The ruling, issued after a four-day bench trial, confirmed the validity of the three patents.

U.S. District Judge Renee Marie Bumb ordered the companies to jointly submit a proposed form of final judgment consistent with the order by Aug. 25.